Intellia is a clinical-stage gene editing company focused on developing innovative CRISPR-based therapies ... protein for the treatment of transthyretin (ATTR) amyloidosis, a rare, progressive ...

We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

Editas' in vivo CRISPR pipeline is still in the early ... in collaboration with Regeneron (REGN). Next-z targets transthyretin amyloidosis (ATTR), which the company projects will have a $12 ...

For example, Intellia Therapeutics’ NTLA-2001, an in vivo CRISPR therapy for transthyretin amyloidosis (ATTR), has shown remarkable ... Phase 1/2 clinical trials are underway, and early data suggests ...

Apart from gene therapies and immunotherapies, scientists also consider the repair of DNA mutation with CRISPR and other genetic engineering ... Pfizer Tafamidis is an approved medication for ...